Real-World outcomes of adalimumab in adults with non-infectious uveitis

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Leal, I (Author) Other; Wong, SW (Author) Other; Giuffre, C (Author) Other; Patil, A (Author) Other; Sousa, DC (Author) Other; Barbosa Breda, J (Author) FMUP; Chhabra, R (Author) Other; Jones, NP (Author) Other; Steeples, LR (Author) Other

Journal

Title: Acta Ophthalmologica

Vol. 100

ISSN: 1755-375X

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 0 Citations

Other information

Authenticus ID: P-00W-A4H

DOI: 10.1111/aos.15120

Abstract (EN): PurposeTo present real-world adalimumab (ADA) efficacy and safety outcomes in non-infectious uveitis (NIU) from a single United Kingdom (UK) tertiary centre. MethodsRetrospective review of adult patients with NIU treated with ADA. Data were collected at baseline, 6 and 12months. The primary goal was to evaluate the rate of treatment failure, using the VISUAL-I/II studies criteria, during 12months of follow-up. Secondary aims were to quantify corticosteroid-sparing effect; to identify safety issues; to assess change in visual acuity; to identify reasons for treatment failure and to compare treatment outcomes at 6 and 12months for patients classified as active or inactive at baseline. ResultsFifty-one patients (102 eyes) with mean age of 48.3years were included. One third had a known underlying systemic disease and 47.6% had panuveitis. The most common indication for ADA was failure to respond to oral immunosuppression. Treatment failure occurred in 9/51 patients (10 eyes) after 6months and 13/51 (20 eyes) patients after 12months. The need for rescue treatment in the 12months prior to ADA was significantly associated with treatment failure at 12months. The mean prednisolone dosage was <10mg/day at 6 and 12months. There were no serious adverse events. ConclusionPatients with NIU who received ADA therapy for 12months were likely to achieve disease control, to stabilize or improve visual acuity, to experience a reduction in immunosuppression and to reduce corticosteroid dosage. No new safety events were observed.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7